Immunocore Holdings plc (IMCR) FY2026 Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
Immunocore Holdings plc cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Increase in accrued expenses → operating reconciliation: $27,001,000.00Share-based compensation expense → operating reconciliation: $9,404,000.00(Increase) decrease in prepayments and other current assets → operating reconciliation: $2,097,000.00Depreciation → operating reconciliation: $1,026,000.00Unrealized foreign exchange gains, net → operating reconciliation: $808,000.00Non-cash lease expense → operating reconciliation: $610,000.00Other → operating reconciliation: $546,000.00operating reconciliation → Net cash from operating activities: $15,928,000.00operating reconciliation → Net income (loss): $808,000.00operating reconciliation → Increase in accounts receivable: $14,621,000.00operating reconciliation → Increase (decrease) in accounts payable: $4,803,000.00operating reconciliation → Unrealized gains on marketable securities: $3,071,000.00operating reconciliation → Decrease in operating lease liabilities: $1,360,000.00operating reconciliation → Decrease in other operating assets: $755,000.00operating reconciliation → Decrease in deferred revenue: $146,000.00Proceeds from exercise of share options → financing reconciliation: $16,485,000.00financing reconciliation → Net cash from financing activities: $16,485,000.00Net cash used in investing activities → investing reconciliation: $786,000.00investing reconciliation → Purchase of property and equipment: $786,000.00Exchange-rate effect → Cash sources and uses: $618,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $452,675,000.00Net cash from operating activities → Cash sources and uses: $15,928,000.00Net cash from financing activities → Cash sources and uses: $16,485,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $484,920,000.00Cash sources and uses → Net cash used in investing activities: $786,000.00Net income (loss): -$808,000.00Net income (loss)−$808.00 KShare-based compensation expense: $9,404,000.00Stock-based compensation+$9.40 MDecrease in operating lease liabilities: -$1,360,000.00Operating lease liabilities−$1.36 MDepreciation: $1,026,000.00Depreciation expense+$1.03 MUnrealized foreign exchange gains, net: $808,000.00Unrealized FX gain & loss+$808.00 KOther: $546,000.00Other non-cash items+$546.00 KNon-cash lease expense: $610,000.00Operating lease amortization+$610.00 KIncrease in accounts receivable: -$14,621,000.00Accounts receivable−$14.62 M(Increase) decrease in prepayments and other current assets: $2,097,000.00Prepaid & other assets+$2.10 MIncrease (decrease) in accounts payable: -$4,803,000.00Accounts payable−$4.80 MIncrease in accrued expenses: $27,001,000.00Accrued liabilities+$27.00 MDecrease in other operating assets: -$755,000.00Other operating assets−$755.00 KUnrealized gains on marketable securities: -$3,071,000.00Unrealized securities gain/loss−$3.07 MDecrease in deferred revenue: -$146,000.00Deferred revenue−$146.00 KNet cash from operating activities: $15,928,000.00Operating cash+$15.93 Moperating reconciliation: $41,492,000.00Proceeds from exercise of share options: $16,485,000.00Stock option exercises+$16.49 MNet cash from financing activities: $16,485,000.00Financing cash+$16.49 Mfinancing reconciliation: $16,485,000.00Proceeds from sale of marketable securities: $0.00Purchase of property and equipment: -$786,000.00PP&E purchases−$786.00 KPurchase of marketable securities: $0.00Net cash used in investing activities: -$786,000.00. Cash required to fund net payments.Investing cash−$786.00 Kinvesting reconciliation: $786,000.00Cash sources and uses: $485,706,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $452,675,000.00Beginning cash$452.68 MEnding cash: Cash, cash equivalents, and restricted cash: $484,920,000.00Ending cash$484.92 MExchange-rate effect: $618,000.00FX effect+$618.00 KCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsNet loss −$808.00K + net operating adjustments $16.74M = operating cash +$15.93MFree cash flow$15.14 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change+$32.25 MEnding cash − beginning cash
Chart details

Immunocore Holdings plc cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
452,675,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
15,928,000 US dollars. Net cash provided.
Net income (loss)
negative 808,000 US dollars
Share-based compensation expense
9,404,000 US dollars
Decrease in operating lease liabilities
negative 1,360,000 US dollars
Depreciation
1,026,000 US dollars
Unrealized foreign exchange gains, net
808,000 US dollars
Other
546,000 US dollars
Non-cash lease expense
610,000 US dollars
Increase in accounts receivable
negative 14,621,000 US dollars
(Increase) decrease in prepayments and other current assets
2,097,000 US dollars
Increase (decrease) in accounts payable
negative 4,803,000 US dollars
Increase in accrued expenses
27,001,000 US dollars
Decrease in other operating assets
negative 755,000 US dollars
Unrealized gains on marketable securities
negative 3,071,000 US dollars
Decrease in deferred revenue
negative 146,000 US dollars
Investing activities
negative 786,000 US dollars. Net cash used.
Proceeds from sale of marketable securities
0 US dollars
Purchase of property and equipment
negative 786,000 US dollars
Purchase of marketable securities
0 US dollars
Financing activities
16,485,000 US dollars. Net cash provided.
Proceeds from exercise of share options
16,485,000 US dollars
Operating adjustment reconciliation
41,492,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
16,485,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
786,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
618,000 US dollars
Ending cash on Jun 30, 2026
484,920,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
485,706,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
32,245,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
15,928,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
786,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
15,142,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$808.00K + net operating adjustments $16.74M = operating cash +$15.93M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 15,928,000 US dollars minus 786,000 US dollars equals 15,142,000 US dollars.
Immunocore Holdings plc (IMCR) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!